Invivyd to Pursue Rapid Immunobridging Pathway to Potential EUA for Treatment of COVID-19 in Moderately to Severely Immunocompromised People, Based on U.S. FDA Feedback
Invivyd to Host Conference Call Discussing First Quarter 2024 Financial Results and Business Highlights [Yahoo! Finance]
Invivyd to Host Conference Call Discussing First Quarter 2024 Financial Results and Business Highlights
Invivyd cuts 14 positions, expects to end 2024 with at least $75M in cash [Seeking Alpha]
Invivyd Announces $20 Million to $25 Million Improvement in Projected 2024 Year-End Cash Position